Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Director Robert Paul Harris sold 150,000 shares of the business’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $5.82, for a total transaction of $873,000.00. Following the completion of the sale, the director now directly owns 669,094 shares of the company’s stock, valued at $3,894,127.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) opened at 5.29 on Wednesday. Aralez Pharmaceuticals Inc. has a 12 month low of $3.10 and a 12 month high of $8.89. The stock’s market capitalization is $345.12 million. The company has a 50-day moving average of $5.05 and a 200-day moving average of $4.16.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.08. Aralez Pharmaceuticals had a negative return on equity of 73.21% and a negative net margin of 224.35%. The business earned $12.60 million during the quarter, compared to analyst estimates of $9.70 million. Aralez Pharmaceuticals’s quarterly revenue was up 142.3% compared to the same quarter last year. On average, equities research analysts expect that Aralez Pharmaceuticals Inc. will post ($1.05) EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. Bank of Montreal Can acquired a new stake in Aralez Pharmaceuticals during the second quarter valued at about $100,000. Goldman Sachs Group Inc. acquired a new stake in Aralez Pharmaceuticals during the first quarter valued at about $109,000. Advisor Group Inc. acquired a new stake in Aralez Pharmaceuticals during the second quarter valued at about $118,000. Knott David M acquired a new stake in Aralez Pharmaceuticals during the second quarter valued at about $124,000. Finally, Alpine Partners VI LLC acquired a new stake in Aralez Pharmaceuticals during the second quarter valued at about $133,000. 49.63% of the stock is owned by institutional investors.

A number of brokerages recently weighed in on ARLZ. Guggenheim reissued a “buy” rating and issued a $12.00 price target on shares of Aralez Pharmaceuticals in a research report on Thursday, September 15th. Chardan Capital reissued a “buy” rating and issued a $10.00 price target on shares of Aralez Pharmaceuticals in a research report on Friday, September 16th.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

5 Day Chart for NASDAQ:ARLZ

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.